#### *Supporting Information for*

# **Pd(II) complexes with pyridine ligands: substituent effects on NMR data, crystal structures and catalytic activity**

*Gracjan Kurpik,[a, b] Anna Walczak,[a, b] Mateusz Gołdyn,[a] Jack Harrowfield,[c] and Artur R. Stefankiewicz\*[a, b]*

- *[a] Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61- 614 Poznań, Poland*
- *[b] Center for Advanced Technology, Uniwersytetu Poznańskiego 10, 61-614 Poznań, Poland*
- *[c] ISIS, Université de Strasbourg, 8 allée Gaspard Monge, 67083 Strasbourg, France*

# **Table of contents**





## <span id="page-2-0"></span>**1. Synthesis of ligands**

## **1.1. N-phenyl-1-(pyridin-4-yl)methanimine (L10)**

The ligand L10 was prepared according to a literature procedure.<sup>1</sup> The reaction of 4-pyridinecarboxaldehyde (1.95 mL, 20.73 mmol) with aniline (1.89 mL, 20.73 mmol) gave **L10** as a white solid. Yield: 85%, 3.21 g.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.77 (d, J = 6.0 Hz, 2H, H<sup>1</sup>), 8.46 (s, 1H, H<sup>3</sup>), 7.76 (d, J = 6.0 Hz, 2H, H<sup>2</sup>), 7.43 (t, J = 7.6 Hz, 2H, H<sup>5</sup>), 7.33 – 7.22 (m, 3H, H<sup>4, 6</sup>).

<sup>1</sup>H NMR results are in a good accordance with data in the literature.<sup>2</sup>



Figure S1. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of N-phenyl-1-(pyridin-4-yl)methanimine (L10).

### **1.2.** *N***-phenylisonicotinamide (L11)**

The ligand L11 was prepared according to a literature procedure.<sup>3</sup> The reaction of isonicotinic acid (2.00 g, 16.24 mmol) with thionyl chloride (15.00 mL), and next aniline (1.48 mL, 16.24 mmol) gave **L11** as a light yellow solid. Yield: 97%, 3.11 g.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.78 (d, J = 6.1 Hz, 2H, H<sup>1</sup>), 8.01 (s, 1H, H<sup>6</sup>), 7.70 (d, J = 6.1 Hz, 2H, H<sup>2</sup>), 7.64 (d, J = 7.6 Hz, 2H, H<sup>3</sup>), 7.39 (t, J = 7.7 Hz, 2H, H<sup>4</sup>), 7.20 (t, J = 7.4 Hz, 1H,  $H<sup>5</sup>$ ).

<sup>1</sup>H NMR results are in a good accordance with data in the literature.<sup>4</sup>



**Figure S2.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl3) of *N*-phenylisonicotinamide (**L11**).

## **1.3. 4,4-dimethyl-1-(pyridin-4-yl)pentane-1,3-dione (L12)**

The ligand L12 was prepared according to a literature procedure.<sup>5</sup> The reaction of methyl isonicotinate (5.00 g, 36.5 mmol) with pinacolone (6.41 mL, 51.1 mmol) gave **L12** as a brown oil. Yield: 78%, 5.82 g.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 16.09 (s, 1H, H<sup>5</sup>), 8.75 (dd, J = 6.5, 2.6 Hz, 2H, H<sup>1</sup>), 7.69 (dd,  $J = 6.5, 2.8$  Hz, 2H, H<sup>2</sup>), 6.34 (s, 1H, H<sup>3</sup>), 1.26 (s, 9H, H<sup>4</sup>).

<sup>1</sup>H NMR results are in a good accordance with data in the literature.<sup>5</sup>



Figure S3. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4,4-dimethyl-1-(pyridin-4-yl)pentane-1,3-dione (**L12**).

#### <span id="page-4-0"></span>**2. Synthetic methods for Pd(II) complexes**



**Scheme S1.** Reaction scheme for the preparation of  $[PdL_2Cl_2]$ .

**Method I.** Ligand  $L1 - L12$  ( $\sim 0.2$  mmol, 2 equiv.) was added to an acetonitrile solution of PdCl<sub>2</sub>  $\sim$  0.1 mmol, 1 equiv. in 5 mL MeCN). After, the resulting mixture was heated under reflux for 12 h. The precipitate that formed was centrifuged off, washed with MeCN (10 mL) and  $Et<sub>2</sub>O$  (2 x 10 mL), and dried under vacuum.



**Scheme S2.** Reaction scheme for the preparation of  $[PdL_2(NO_3)_2]$ .

**Method II.** Ligand  $L1 - L12$  ( $\sim 0.2$  mmol, 2 equiv. ) was added to an acetonitrile solution of Pd( $NO<sub>3</sub>_2$ :  $2H<sub>2</sub>O$  (~0.1 mmol, 1 equiv. in 5 mL MeCN). After, the resulting mixture was heated under reflux for 12 h. The solvent was then evaporated under reduced pressure. The crude

product was redissolved in MeCN  $(1 \text{ mL})$  and reprecipitated by the addition of Et<sub>2</sub>O  $(10 \text{ mL})$ . This precipitate was centrifuged off, washed with  $Et<sub>2</sub>O$  (2 x 10 mL), and dried under vacuum.



**Scheme S3.** Reaction scheme for the preparation of  $[PdL_4](NO_3)_2$ .

**Method III.** To a suspension of  $PdCl_2$  ( $\sim$ 0.1 mmol, 1 equiv.) in EtOH (5 mL), a solution of ligand **L1 – L12** ( $\sim$ 1.0 mmol, 10 equiv.) in DCM (5 mL) was added, and the resulting mixture was stirred at room temperature for 1 h. After, AgNO<sub>3</sub> ( $\sim$ 0.2 mmol, 2 equiv.) in 0.5 mL H<sub>2</sub>O was added and the resulting suspension was stirred for an additional 12 h excluding light. The reaction mixture was filtered to remove AgCl, then the filtrate was evaporated under reduced pressure. The crude product was redissolved in DCM (1 mL) and reprecipitated by the addition of *n*-hexane (10 mL). This precipitate was centrifuged off, washed with *n*-hexane (2 x 10 mL), and dried under vacuum.



**Scheme S4.** Reaction scheme for the preparation of  $[PdL_4](NO_3)_2$ .

**Method IV.** To a suspension of  $Pd(DMSO)<sub>2</sub>C<sub>2</sub> (~0.1 mmol, 1 equiv.)$  in EtOH (5 mL), a solution of ligand  $L1 - L12$  ( $\sim$ 1.0 mmol, 10 equiv.) in DCM (5 mL) was added, and the resulting mixture was stirred at room temperature for 1 h. After, AgNO<sub>3</sub> ( $\sim$ 0.2 mmol, 2 equiv.) in 0.5 mL H<sub>2</sub>O was added and the resulting suspension was stirred for an additional 12 h excluding light. The reaction mixture was filtered to remove AgCl, then the filtrate was evaporated under reduced pressure. The crude product was redissolved in DCM (1 mL) and reprecipitated by the addition of *n*-hexane (10 mL). This precipitate was centrifuged off, washed with *n*-hexane (2 x 10 mL), and dried under vacuum.

#### <span id="page-5-0"></span>**3. Characterization of Pd(II) complexes**

#### <span id="page-5-1"></span>**3.1. Pd(II) complexes based on pyridine (L1)**

[Pd(L1)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (19.5 mg, 0.11) mmol) and **L1** (17.7 µL, 0.22 mmol). Yield: 74%, 27.3 mg.

<sup>1</sup>H NMR (300 MHz, CDCl3) δ = 8.84 (d, *J* = 5.3 Hz, 2H), 7.79 (t, *J* = 7.8 Hz, 1H), 7.35 (t, *J* = 7.3 Hz, 2H).

ESI-MS calcd. for  $[Pd(L1)_2Cl_2+Na]^+$   $[M+Na]^+$ :  $m/z = 358.9139$ , observed:  $m/z = 358.9141$ .

 $[Pd(L1)_2(NO_3)_2]$ : The mixture of complexes was prepared according to the method II, using Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (25.2 mg, 0.09 mmol) and L1 (15.2 µL, 0.19 mmol). Yield: 69%, 25.2 mg.

*trans*-[Pd(**L1**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (90%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.61 (d, *J* = 5.0 Hz, 2H), 7.92 (t, *J* = 7.9 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H).

 $c$ *is*-[Pd(**L1**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (10%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.72 (d, *J* = 5.3 Hz, 2H), 7.84 (t, *J* = 7.8 Hz, 1H), 7.41 (t, *J* = 7.5 Hz, 2H).

ESI-MS calcd. for  $[Pd(L1)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 325.9756, observed:  $m/z$  = 325.9762.

[Pd(**L1**)4](NO3)2: The complex was prepared according to the following procedure.  $Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O$  (30.1 mg, 0.11 mmol) was suspended in pyridine (5 mL) and heated under reflux for 12 h. The solvent was then evaporated under reduced pressure. The product was washed with chloroform (10 mL) and diethyl ether (2 x 10 mL), and dried under vacuum. Yield: 71%, 43.9 mg.

<sup>1</sup>H NMR (300 MHz, CDCl3) δ = 9.63 (d, *J* = 5.3 Hz, 2H), 7.76 (t, *J* = 7.6 Hz, 1H), 7.44 (t, *J* = 7.4 Hz, 2H).

ESI-MS calcd. for  $[{\rm Pd}(L1)_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z = 211.0360$ , observed:  $m/z = 211.0357$ .

Table S1. <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L1 and Pd(II) complexes based on this ligand.

	L1	[Pd(L1) <sub>2</sub> Cl <sub>2</sub> ]		trans- $[Pd(L1)2(NO3)2]$		$CIS-$ $[Pd(L1)2(NO3)2]$		$[Pd(L1)_4](NO_3)_2$	
			Δδ		Δδ		Δδ		Δδ
$\mathsf{H}^1$	8.62	8.84	0.22	8.61	-0.01	8.72	0.10	9.63	1.01
H <sup>2</sup>	7.29	7.35	0.06	7.48	0.19	7.41	0.12	7.44	0.15
Нз	.68	7.79	0.11	7.92	0.24	7.84	0.16	7.76	0.08



**Figure S4.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on pyridine (**L1**).



**Figure S5.** ESI-MS analysis of Pd(II) complexes based on pyridine (**L1**), showing the observed data (bottom) and the theoretical isotope model (top).

## <span id="page-7-0"></span>**3.2. Pd(II) complexes based on 4-methylpyridine (L2)**

[Pd(L2)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (25.0 mg, 0.14) mmol) and **L2** (27.4 µL, 0.28 mmol). Yield: 73 %, 37.4 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.63 (d, *J* = 6.7 Hz, 2H), 7.13 (d, *J* = 6.4 Hz, 2H), 2.40 (s, 3H).

ESI-MS calcd. for  $[Pd(L2)_2Cl_2+Na]^+$   $[M+Na]^+$ :  $m/z = 386.9452$ , observed:  $m/z = 386.9468$ .

 $[Pd(L2)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>]$ : The mixture of complexes was prepared according to the method II, using Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (26.2 mg, 0.10 mmol) and **L2** (19.1 µL, 0.20 mmol). Yield: 57%, 23.4 mg.

*trans*-[Pd(**L2**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (92%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.40 (d, *J* = 6.6 Hz, 2H), 7.25 (d, *J* = 6.1 Hz, 2H), 2.46 (s, 3H).

 $cis$ -[Pd(**L2**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (8%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.51 (d, *J* = 6.6 Hz, 2H), 7.19 (d, *J* = 6.0 Hz, 2H), 2.43 (s, 3H).

ESI-MS calcd. for  $[Pd(L2)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 354.0070, observed:  $m/z$  = 354.0088.

 $[Pd(L2)_4](NO_3)_2$ : The complex was prepared according to the method III, using PdCl<sub>2</sub> (21.6 mg, 0.12 mmol) and **L2** (118.5 µL, 1.22 mmol). Yield: 89%, 65.4 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.32 (d, J = 6.6 Hz, 2H), 7.18 (d, J = 6.6 Hz, 2H), 2.30 (s, 3H). ESI-MS calcd. for  $[{\rm Pd}(\text{L2})_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z = 239.0674$ , observed:  $m/z = 239.0678$ .

**Table S2.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl3 for ligand **L2** and Pd(II) complexes based on this ligand.



**Figure S6.** 1H NMR spectra of Pd(II) complexes based on 4-methylpyridine (**L2**).



**Figure S7.** ESI-MS analysis of Pd(II) complexes based on 4-methylpyridine (**L2**), showing the observed data (bottom) and the theoretical isotope model (top).

#### <span id="page-9-0"></span>**3.3. Pd(II) complexes based on 4-methoxypyridine (L3)**

 $[Pd(L3)_2C]_2$ : The complex was prepared according to the method I, using PdCl<sub>2</sub> (23.4 mg, 0.13) mmol) and **L3** (26.8 µL, 0.26 mmol). Yield: 68%, 35.3mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.59 (d, *J* = 7.2 Hz, 2H), 6.81 (d, *J* = 7.2 Hz, 2H), 3.88 (s, 3H).

ESI-MS calcd. for  $[Pd(L3)_2Cl_2+Na]^+$   $[M+Na]^+$ :  $m/z = 418.9351$ , observed:  $m/z = 418.9360$ .

 $[Pd(L3)_{2}(NO_{3})_{2}]$ : The mixture of complexes was prepared according to the method II, using Pd(NO3)2·2H2O (26.5 mg, 0.10 mmol) and **L3** (20.2 µL, 0.20 mmol). Yield: 47%, 21.0 mg.

*trans*-[Pd(**L3**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (93%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.33 (d, J = 7.2 Hz, 2H), 6.91 (d, J = 7.2 Hz, 2H), 3.91 (s, 3H).

 $c$ *is*-[Pd(**L3**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (7%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.45 (d, *J* = 7.1 Hz, 2H), 6.85 (d, *J* = 7.1 Hz, 2H), 3.89 (s, 3H).

ESI-MS calcd. for  $[Pd(L3)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 385.9968, observed:  $m/z$  = 385.9977.

 $[Pd(L3)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$ : The complex was prepared according to the method III, using PdCl<sub>2</sub> (23.0 mg, 0.13 mmol) and **L2** (131.7 µL, 1.30 mmol). Yield: 85%, 73.5 mg.

<sup>1</sup>H NMR (300 MHz, CDCl3) δ = 9.21 (d, *J* = 7.2 Hz, 2H), 6.87 (d, *J* = 7.2 Hz, 2H), 3.79 (s, 3H). ESI-MS calcd. for  $[{\rm Pd}(L3)_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z = 271.0572$ , observed:  $m/z = 271.0571$ .

	L <sub>3</sub>	[Pd(L3) <sub>2</sub> Cl <sub>2</sub> ]		trans- $[Pd(L3)2(NO3)2]$			cis- $[Pd(L3)2(NO3)2]$		$[Pd(L3)4](NO3)2$	
H <sup>1</sup> H <sup>2</sup> $H^3$	δ 8.41 6.79 3.83	δ 8.59 6.81 3.88		Δδ 0.18 0.02 0.05	δ 8.33 6.91 3.91	Δδ $-0.08$ 0.12 0.08	δ 8.45 6.85 3.89	Δδ 0.04 0.06 0.06	δ 9.21 6.87 3.79	Δδ 0.80 0.08 $-0.04$
			$H^3$		H <sup>1</sup>			H <sup>2</sup>		$H^3$
	CI <sup>-</sup> Pd <sup>II</sup> CI.									
	NO <sub>3</sub> $Pd^{\parallel}$ NO <sub>3</sub> cis/trans forms									
	$Pd^{\parallel}$		$2+$ 2 NO <sub>3</sub>							
	$10.5$	$10.0\,$	9.5	$9.0\,$	8.5	$\bf 8.0$ $f1$ (ppm)	7.5	$\bf 7.0$ 6.5	$\bf 6.0$	$4.0\,$ 3.5

Table S3. <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L3 and Pd(II) complexes based on this ligand.

**Figure S8.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on 4-methoxypyridine (**L3**).



**Figure S9.** ESI-MS analysis of Pd(II) complexes based on 4-methoxypyridine (**L3**), showing the observed data (bottom) and the theoretical isotope model (top).

#### <span id="page-11-0"></span>**3.4. Pd(II) complexes based on methyl isonicotinate (L4)**

 $[Pd(L4)_2C_2]$ : The complex was prepared according to the method I, using PdCl<sub>2</sub> (23.1 mg, 0.13) mmol) and **L4** (30.7 µL, 0.26 mmol). Yield: 80%, 47.1 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.01 (d, J = 6.7 Hz, 2H), 7.90 (d, J = 6.7 Hz, 2H), 3.99 (s, 3H).

ESI-MS calcd. for  $[Pd(L4)_2Cl_2+Na]^+$   $[M+Na]^+$ :  $m/z = 474.9250$ , observed:  $m/z = 474.9263$ .

 $[Pd(L4)_{2}(NO_{3})_{2}]$ : The mixture of complexes was prepared according to the method II, using Pd(NO3)2·2H2O (24.3 mg, 0.09 mmol) and **L4** (21.5 µL, 0.18 mmol). Yield: 64%, 29.5 mg.

*trans*-[Pd(**L4**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (95%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.78 (d, *J* = 6.7 Hz, 2H), 8.03 (d, *J* = 6.7 Hz, 2H), 4.01 (s, 3H).

 $c$ *is*-[Pd(**L4**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (5%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.89 (d, *J* = 6.7 Hz, 2H), 7.96 (d, *J* = 6.7 Hz, 2H), 4.00 (s, 3H).

ESI-MS calcd. for [Pd(L4)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>+MeCN+Li]<sup>+</sup> [M+MeCN+Li]<sup>+</sup>: *m/z* = 552.0172, observed: *m/z*  $= 552.0177.$ 

 $[Pd(L4)<sub>d</sub>](NO<sub>3</sub>)$ . The complex was prepared according to the method III, using PdCl<sub>2</sub> (21.8 mg, 0.12 mmol) and **L4** (145.2 µL, 1.23 mmol). Yield: 76%, 72.8 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.80 (d, J = 6.6 Hz, 2H), 7.98 (d, J = 6.6 Hz, 2H), 3.91 (s, 3H).

ESI-MS calcd. for  $[{\rm Pd}({\rm L4})_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z = 327.0471$ , observed:  $m/z = 327.0471$ .

**Table S4.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl3 for ligand **L4** and Pd(II) complexes based on this ligand.

	L4	[Pd(L4) <sub>2</sub> Cl <sub>2</sub> ]		trans- $[Pd(L4)2(NO3)2]$		$CIS-$ $[Pd(L4)2(NO3)2]$		$[Pd(L4)4] (NO3)2$	
			Δδ		Δδ		Δδ		Δδ
Н1	8.79	9.01	0.22	8.78	$-0.01$	8.89	0.10	9.80	1.01
Н2	.84	7.90	0.06	8.03	0.19	7.96	0.12	7.98	0.14
Нз	3.96	3.99	0.03	4.01	0.05	4.00	0.04	3.91	$-0.05$



**Figure S10.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on methyl isonicotinate (**L4**).



**Figure S11.** ESI-MS analysis of Pd(II) complexes based on methyl isonicotinate (**L4**), showing the observed data (bottom) and the theoretical isotope model (top).

#### <span id="page-12-0"></span>**3.5. Pd(II) complexes based on methyl 4-acetylpyridine (L5)**

[Pd(L5)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (20.9 mg, 0.12) mmol) and **L5** (26.1 µL, 0.24 mmol). Yield: 89%, 44.0 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 9.05 (d, J = 6.1 Hz, 2H), 7.78 (d, J = 6.1 Hz, 2H), 2.65 (s, 3H).

ESI-MS calcd. for  $[Pd(L5)_2Cl+DMSO]^+$   $[M-Cl+DMSO]^+$ :  $m/z = 462.9909$ , observed:  $m/z =$ 462.9903.

 $[Pd(L5)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>]$ : The mixture of complexes was prepared according to the method II, using Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (27.0 mg, 0.10 mmol) and **L5** (22.4 µL, 0.20 mmol). Yield: 67%, 32.1 mg.

*trans*-[Pd(**L5**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (91%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.82 (d, *J* = 6.3 Hz, 2H), 7.91 (d, *J* = 6.3 Hz, 2H), 2.68 (s, 3H).

 $cis$ -[Pd(**L5**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (9%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.94 (d, *J* = 6.5 Hz, 2H), 7.85 (d, *J* = 6.5 Hz, 2H), 2.66 (s, 3H).

ESI-MS calcd. for  $[Pd(L5)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 409.9969, observed:  $m/z$  = 409.9971.

 $[Pd(L5)_{4}]$ (NO<sub>3</sub>)<sub>2</sub>: The complex was prepared according to the method IV, using Pd(DMSO)<sub>2</sub>Cl<sub>2</sub> (29.8 mg, 0.09 mmol) and **L5** (98.8 µL, 0.90 mmol). Yield: 65%, 41.5 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.87 (d, J = 6.7 Hz, 2H), 7.88 (d, J = 6.7 Hz, 2H), 2.55 (s, 3H).

ESI-MS calcd. for  $[{\rm Pd}({\bf L5})_4]^{2+}$  [M-2NO<sub>3</sub>]<sup>2+</sup>:  $m/z$  = 295.0573, observed:  $m/z$  = 295.0571.

**Table S5.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl3 for ligand **L5** and Pd(II) complexes based on this ligand.



**Figure S12.** 1H NMR spectra of Pd(II) complexes based on 4-acetylpyridine (**L5**).



**Figure S13.** ESI-MS analysis of Pd(II) complexes based on 4-acetylpyridine (**L5**), showing the observed data (bottom) and the theoretical isotope model (top).

### <span id="page-14-0"></span>**3.6. Pd(II) complexes based on 4-(dimethylaminio)pyridine (L6)**

[Pd(L6)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (20.0 mg, 0.11) mmol) and **L6** (27.6 mg, 0.22 mmol). Yield: 77%, 36.6 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 8.25 (d, J = 7.3 Hz, 2H), 6.40 (d, J = 7.3 Hz, 2H), 3.02 (s, 6H).

ESI-MS calcd. for  $[Pd(L6)_2Cl_2+Na]^+$   $[M+Na]^+$ :  $m/z = 444.9984$ , observed:  $m/z = 444.9981$ .

 $[Pd(\mathsf{L6})_4]$ (NO<sub>3</sub>)<sub>2</sub>: The complex was prepared according to the method IV, using Pd(DMSO)<sub>2</sub>Cl<sub>2</sub> (32.9 mg, 0.10 mmol) and **L6** (120.5 mg, 0.99 mmol). Yield: 81%, 57.4 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.71 (d, J = 7.3 Hz, 2H), 6.43 (d, J = 7.4 Hz, 2H), 2.93 (s, 6H).

ESI-MS calcd. for  $[{\rm Pd}({\rm L6})_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z$  = 297.1205, observed:  $m/z$  = 297.1206.

Table S6. <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L6 and Pd(II) complexes based on this ligand.

	L6		[Pd(L6) <sub>2</sub> Cl <sub>2</sub> ]		$[Pd(L6)4](NO3)2$
			Δδ		Δδ
H <sup>1</sup>	8.21	8.25	0.04	8.71	0.50
H <sup>2</sup>	6.47	6.40	$-0.07$	6.43	$-0.04$
$H^3$	2.99	3.02	0.03	2.93	$-0.06$



**Figure S14.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on 4-(dimethylaminio)pyridine (**L6**).



**Figure S15.** ESI-MS analysis of Pd(II) complexes based on 4-(dimethylaminio)pyridine (**L6**), showing the observed data (bottom) and the theoretical isotope model (top).

## <span id="page-15-0"></span>**3.7. Pd(II) complexes based on 4-chloropyridine (L7)**

 $[Pd(L7)_2Cl_2]$ : The complex was prepared according to the following procedure. K<sub>2</sub>CO<sub>3</sub> (359.3) mg, 2.6 mmol) was added to the suspension of 4-chloropyridine hydrochloride (39.0 mg, 0.26 mmol) in acetonitrile (5 mL) and stirred in ice bath for 3 h. After, the solid residue was filtered off and ligand L7 in the form of acetonitrile solution was added to a hot solution of PdCl<sub>2</sub> (23.0) mg, 0.13 mmol). The resulting mixture was heated under reflux for 12 h. The precipitate that formed was centrifuged off, washed with MeCN (10 mL) and  $Et<sub>2</sub>O$  (2 x 10 mL), and dried under vacuum. Yield: 69%, 36.2 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.75 (d, J = 6.9 Hz, 2H), 7.37 (d, J = 6.9 Hz, 2H). ESI-MS calcd. for [Pd(L7)<sub>2</sub>Cl]<sup>+</sup> [M-Cl]<sup>+</sup>: *m*/z = 368.8769, observed: *m*/z = 368.8772.

 $[Pd(L7)_{2}(NO_{3})_{2}]$ : The mixture of complexes was prepared according to the following procedure.  $K<sub>2</sub>CO<sub>3</sub>$  (304.1 mg, 2.20 mmol) was added to the suspension of 4-chloropyridine hydrochloride (33.0 mg, 0.22 mmol) in acetonitrile (5 mL) and stirred in ice bath for 3 h. After, the solid residue was filtered off and ligand **L7** in the form of acetonitrile solution was added to a hot solution of  $Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O$  (29.3 mg, 0.11 mmol). The resulting mixture was heated under reflux for 12 h. The solvent was then evaporated under reduced pressure. The crude product was redissolved in MeCN (1 mL) and reprecipitated by the addition of  $Et<sub>2</sub>O$  (10 mL). This precipitate was centrifuged off, washed with  $Et_2O$  (3 x 10 mL), and dried under vacuum. Yield: 58%, 29.2 mg.

*trans*-[Pd(L7)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (95%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.50 (d, *J* = 6.9 Hz, 2H), 7.50 (d, *J* = 6.9 Hz, 2H).

*cis*-[Pd(**L7**)2(NO3)2] (5%): <sup>1</sup>H NMR (300 MHz, CDCl3) δ = 8.61 (d, *J* = 6.7 Hz, 2H), 7.43 (d, *J* = 6.7 Hz, 2H).

ESI-MS calcd. for  $[Pd(L7)_2(NO_3)]^+$   $[M-NO_3]^+$ :  $m/z = 395.8963$ , observed:  $m/z = 395.8973$ .

 $[Pd(L7)<sub>4</sub>](NO<sub>3</sub>)$ <sup>2</sup>: The complex was prepared according to the following procedure.

 $K_2CO_3$  (1.66 g, 12.0 mmol) was added to the suspension of 4-chloropyridine hydrochloride (180.0 mg, 1.20 mmol) in chloroform (10 mL) and stirred in ice bath for 3 h. After, the solid residue was filtered off. To a suspension of  $Pd(DMSO)_{2}Cl_{2}$  (40.0 mg, 0.12 mmol) in EtOH (5 mL), a chloroform solution of ligand **L7** in DCM (5 mL) was added, and the resulting mixture was stirred at 0 $\degree$ C for 1 h. After, AgNO<sub>3</sub> (40.8 mg, 0.24 mmol) in 0.5 mL H<sub>2</sub>O was added and the resulting suspension was stirred for an additional 12 h excluding light. The reaction mixture was filtered to remove AgCl, then the filtrate was evaporated under reduced pressure. The crude product was redissolved in chloroform (1 mL) and reprecipitated by the addition of *n*hexane (10 mL). This precipitate was centrifuged off, washed with *n*-hexane (3 x 10 mL), and dried under vacuum. Yield: 65%, 53.4 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.52 (d, J = 7.0 Hz, 2H), 7.47 (d, J = 6.9 Hz, 2H).

ESI-MS calcd. for  $[{\rm Pd}({\bf L7})_4]^{2+}$   $[{\rm M-2NO}_3]^{2+}$ :  $m/z = 279.9569$ , observed:  $m/z = 279.9578$ .



**Table S7.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl3 for ligand **L7** and Pd(II) complexes based on this ligand.



**Figure S16.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on 4-chloropyridine (**L7**).



**Figure S17.** ESI-MS analysis of Pd(II) complexes based on 4-chloropyridine (**L7**), showing the observed data (bottom) and the theoretical isotope model (top).

### <span id="page-17-0"></span>**3.8. Pd(II) complexes based on 4-pyridinecarbonitrile (L8)**

[Pd(L8)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (18.5 mg, 0.10) mmol) and **L8** (21.7 mg, 0.21 mmol). Yield: 85%, 34.2 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 9.08 (d, J = 6.8 Hz, 2H), 7.62 (d, J = 6.7 Hz, 2H).

 $[Pd(L8)_2(NO_3)_2]$ : The complex was prepared according to the method II, using Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (24.1 mg, 0.09 mmol) and **L8** (18.8 mg, 0.18 mmol). Yield: 87%, 34.5 mg.

*trans*-[Pd(**L8**)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (69%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.83 (d, *J* = 6.7 Hz, 2H), 7.78 (d, *J* = 6.7 Hz, 2H).

 $cis$ -[Pd(L8)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (31%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.94 (d, *J* = 6.9 Hz, 2H), 7.71 (d, *J*  $= 6.9$  Hz, 2H).

ESI-MS calcd. for  $[Pd(L8)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 375.9661, observed:  $m/z$  = 375.9688.

Table S8. <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L8 and Pd(II) complexes based on this ligand.



**Figure S18.** 1H NMR spectra of Pd(II) complexes based on 4-pyridinecarbonitrile (**L8**).



**Figure S19.** ESI-MS analysis of Pd(II) complex based on 4-pyridinecarbonitrile (**L8**), showing the observed data (bottom) and the theoretical isotope model (top).

### <span id="page-19-0"></span>**3.9. Pd(II) complexes based on 4-(trifluoromethyl)pyridine (L9)**

[Pd(L9)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (21.2 mg, 0.12 mmol) and **L9** (27.8 µL, 0.24 mmol). Yield: 76%, 42.8 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 9.09 (d, J = 6.4 Hz, 2H), 7.62 (d, J = 6.5 Hz, 2H).

ESI-MS calcd. for  $[Pd(L9)_2Cl+DMSO]^+$   $[M-Cl+DMSO]^+$ :  $m/z = 514.9445$ , observed:  $m/z =$ 514.9462.

 $[Pd(L9)_{2}(NO_{3})_{2}]$ : The complex was prepared according to the method II, using Pd(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (23.8 mg, 0.09 mmol) and **L9** (20.7 µL, 0.18 mmol). Yield: 61%, 28.6 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.86 (d, *J* = 6.4 Hz, 2H), 7.77 (d, *J* = 6.5 Hz, 2H).

ESI-MS calcd. for  $[Pd(L9)_2(NO_3)]$ <sup>+</sup>  $[M-NO_3]$ <sup>+</sup>:  $m/z$  = 461.9504, observed:  $m/z$  = 461.9521.

**Table S9.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl3 for ligand **L9** and Pd(II) complexes based on this ligand.

	L9		[Pd(L9) <sub>2</sub> Cl <sub>2</sub> ]		$[Pd(L9)_2(NO_3)_2]$
			Δδ	o	Δδ
H <sup>1</sup>	8.82	9.09	0.27	8.86	0.04
H <sup>2</sup>	7.52	7.62	0.10	7.77	0.25



**Figure S20.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on 4-(trifluoromethyl)pyridine (**L9**).



**Figure S21.** ESI-MS analysis of Pd(II) complexes based on 4-(trifluoromethyl)pyridine (**L9**), showing the observed data (bottom) and the theoretical isotope model (top).

### <span id="page-20-0"></span>**3.10. Pd(II) complexes based on N-phenyl-1-(pyridin-4-yl)methanimine (L10)**

[Pd(**L10**)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (17.5 mg, 0.10 mmol) and **L10** (36.0 mg, 0.20 mmol). Yield: 71%, 38.0 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.97 (d, *J* = 6.6 Hz, 2H), 8.47 (s, 1H), 7.82 (d, *J* = 6.8 Hz, 2H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.28 (d, *J* = 7.3 Hz, 2H).

[Pd(**L10**)4](NO3)2: The complex was prepared according to the method IV, using Pd(DMSO)<sub>2</sub>Cl<sub>2</sub> (33.5 mg, 0.10 mmol) and **L10** (182.2 mg, 1.00 mmol). Yield: 84%, 89.9 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 9.79 (d, J = 6.6 Hz, 2H), 8.39 (s, 1H), 7.93 (d, J = 6.5 Hz, 2H), 7.41 (t, *J* = 7.4 Hz, 2H), 7.30 (t, *J* = 7.3 Hz, 1H), 7.21 (d, *J* = 7.3 Hz, 2H).



Table S10. <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L10 and Pd(II) complexes based on this ligand.



#### <span id="page-21-0"></span>**3.11. Pd(II) complexes based on** *N***-phenylisonicotinamide (L11)**

 $[Pd(L11)_2Cl_2]$ : The complex was prepared according to the method I, using  $PdCl_2$  (20.0 mg, 0.11 mmol) and **L11** (44.7 mg, 0.22 mmol). Yield: 82%, 53.1 mg.

<sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) δ = 10.69 (s, 1H), 8.99 (d, J = 6.8 Hz, 2H), 7.99 (d, J = 6.8 Hz, 2H), 7.76 (d, *J* = 7.7 Hz, 2H), 7.39 (t, *J* = 8.5 Hz, 2H), 7.16 (t, *J* = 7.3 Hz, 1H).

ESI-MS calcd. for  $[Pd(L11)_2Cl+DMSO]^+$   $[M-Cl+DMSO]^+$ :  $m/z = 617.0442$ , observed:  $m/z =$ 617.0437.

[Pd(**L11**)4](NO3)2: The complex was prepared according to the following procedure. To a Schlenk flask, the solution of  $Pd(C_6H_5CN)_2Cl_2$  (37.3 mg, 0.10 mmol) in MeCN (5 mL) and the ligand **L11** (198.2 mg, 1.00 mmol) were placed. The resulting mixture was stirred at room temperature for 0.5 h. After, AgNO<sub>3</sub> (34.0 mg, 0.20 mmol) in 0.5 mL H<sub>2</sub>O was added. The Schlenk flask was sealed and the resulting suspension was stirred for additional 16 h at 65°C excluding light. The reaction mixture was filtered to remove AgCl, then the filtrate was evaporated under reduced pressure. The residue was washed with DCM (10 mL) and diethyl ether (3 x 10 mL), and dried under vacuum. Yield: 64%, 63.7 mg.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 10.62 (s, 1H), 9.44 (d, J = 6.7 Hz, 2H), 8.16 (d, J = 6.8 Hz, 2H), 7.68 (d, *J* = 7.3 Hz, 2H), 7.37 (t, *J* = 7.9 Hz, 2H), 7.15 (t, *J* = 7.0 Hz, 1H).

ESI-MS calcd. for  $[Pd(L11)_4]^{2+}$   $[M-2NO_3]^{2+}$ :  $m/z = 449.1107$ , observed:  $m/z = 449.1123$ .



**Table S11.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in DMSO-*d6* for ligand **L11** and Pd(II) complexes based on this ligand.

**Figure S23.** 1H NMR spectra of Pd(II) complexes based on *N*-phenylisonicotinamide (**L11**).



**Figure S24.** ESI-MS analysis of Pd(II) complexes based on *N*-phenylisonicotinamide (**L11**), showing the observed data (bottom) and the theoretical isotope model (top).

#### <span id="page-23-0"></span>**3.12. Pd(II) complexes based on 4,4-dimethyl-1-(pyridin-4-yl)pentane-1,3 dione (L12)**

[Pd(L12)<sub>2</sub>Cl<sub>2</sub>]: The complex was prepared according to the method I, using PdCl<sub>2</sub> (19.9 mg, 0.11 mmol) and **L12** (46.1 mg, 0.22 mmol). Yield: 70%, 46.2 mg.

<sup>1</sup>H NMR (300 MHz, CDCl3) δ = 15.88 (s, 1H), 8.95 (d, *J* = 6.9 Hz, 2H), 7.73 (d, *J* = 6.9 Hz, 2H), 6.33 (s, 1H), 1.26 (s, 9H).

ESI-MS calcd. for  $[Pd(L12)_2C] + MeCN]^+$   $[M-Cl+MeCN]^+$ :  $m/z = 594.1189$ , observed:  $m/z =$ 594.1170.

 $[Pd(L12)_4](NO_3)_2$ : The complex was prepared according to the method III, using PdCl<sub>2</sub> (23.3) mg, 0.13 mmol) and **L12** (269.7 mg, 1.30 mmol). Yield: 83%, 114.7 mg.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 15.67 (s, 1H), 9.75 (d, J = 6.8 Hz, 2H), 7.83 (d, J = 6.8 Hz, 2H), 6.25 (s, 1H), 1.20 (s, 9H).

ESI-MS calcd. for  $[Pd(L12)_4]^{2+}$   $[M-2NO_3]^{2+}$ :  $m/z = 463.1726$ , observed:  $m/z = 463.1743$ .



**Table S12.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) in CDCl<sub>3</sub> for ligand L12 and Pd(II) complexes based on this ligand.



**Figure S25.** <sup>1</sup>H NMR spectra of Pd(II) complexes based on 4,4-dimethyl-1-(pyridin-4-yl)pentane-1,3 dione (**L12**).



**Figure S26.** ESI-MS analysis of Pd(II) complexes based on 4,4-dimethyl-1-(pyridin-4-yl)pentane-1,3 dione (**L12**), showing the observed data (bottom) and the theoretical isotope model (top).

# <span id="page-25-0"></span>**4. <sup>1</sup>H NMR analysis of Pd(II) complexes based on pyridine ligands**

**Table S13.** <sup>1</sup>H NMR chemical shifts (δ, ppm) and shifts differences (Δδ, ppm) for ligands **L1** – **L12** and Pd(II) complexes based on these ligands.

		L	$[PdL_2Cl_2]$		trans-	$[PdL2(NO3)2]$		$cis$ -[PdL <sub>2</sub> (NO <sub>3</sub> ) <sub>2</sub> ]	$[PdL_4] (NO_3)_2$	
		δ	δ	Δδ	δ	Δδ	δ	Δδ	δ	Δδ
L1	H <sup>1</sup>	8.62	8.84	0.22	8.61	$-0.01$	8.72	0.10	9.63	1.01
	H <sup>2</sup>	7.29	7.35	0.06	7.48	0.19	7.41	0.12	7.44	0.15
	$H^3$	7.68	7.79	0.11	7.92	0.24	7.84	0.16	7.76	0.08
	H <sup>1</sup>	8.45	8.63	0.18	8.40	$-0.05$	8.51	0.06	9.32	0.87
L2	H <sup>2</sup>	7.09	7.13	0.04	7.25	0.16	7.19	0.10	7.18	0.09
	H <sup>3</sup>	2.34	2.40	0.06	2.46	0.12	2.43	0.09	2.30	$-0.04$
L3	H <sup>1</sup>	8.41	8.59	0.18	8.33	$-0.08$	8.45	0.04	9.21	0.80
	H <sup>2</sup>	6.79	6.81	0.02	6.91	0.12	6.85	0.06	6.87	0.08
	H <sup>3</sup>	3.83	3.88	0.05	3.91	0.08	3.89	0.06	3.79	$-0.04$
	H <sup>1</sup>	8.79	9.01	0.22	8.78	$-0.01$	8.89	0.10	9.80	1.01
L4	H <sup>2</sup>	7.84	7.90	0.06	8.03	0.19	7.96	0.12	7.98	0.14
	H <sup>3</sup>	3.96	3.99	0.03	4.01	0.05	4.00	0.04	3.91	$-0.05$
	H <sup>1</sup>	8.79	9.05	0.26	8.82	0.03	8.94	0.15	9.87	1.08
L5	H <sup>2</sup>	7.70	7.78	0.08	7.91	0.21	7.85	0.15	7.88	0.18
	$H^3$	2.61	2.65	0.04	2.68	0.07	2.66	0.05	2.55	$-0.06$
L <sub>6</sub>	H <sup>1</sup>	8.21	8.25	0.04	÷,				8.71	0.50
	H <sup>2</sup>	6.47	6.40	$-0.07$					6.43	$-0.04$
	$H^3$	2.99	3.02	0.03					2.93	$-0.06$
L7 L8	H <sup>1</sup> H <sup>2</sup>	8.49	8.75	0.26	8.50	0.01	8.61	0.12	9.52	1.03
	H <sup>1</sup>	7.30 8.79	7.37 9.08	0.07 0.29	7.50 8.83	0.20 0.04	7.43 8.94	0.13 0.15	7.47	0.17
	H <sup>2</sup>	7.52	7.62	0.10	7.78	0.26	7.71	0.19		
L9	H <sup>1</sup>	8.82	9.09	0.27	8.86	0.04				
	H <sup>2</sup>	7.52	7.62	0.10	7.77	0.25				
	H <sup>1</sup>	8.77	8.97	0.20					9.79	1.02
	H <sup>2</sup>	7.76	7.82	0.06					7.93	0.17
	H <sup>3</sup>	8.46	8.47	0.01					8.39	$-0.07$
L10	H <sup>4</sup>	7.24	7.28	0.04					7.21	$-0.03$
	H <sup>5</sup>	7.43	7.45	0.02					7.41	$-0.02$
	H <sup>6</sup>	7.29	7.33	0.04					7.30	0.01
	H <sup>1</sup>	8.79	8.99	0.20					9.44	0.65
	H <sup>2</sup>	7.86	7.99	0.13					8.16	0.30
L11	H <sup>3</sup>	7.77	7.76	$-0.01$					7.68	$-0.09$
	H <sup>4</sup>	7.38	7.39	0.01					7.37	$-0.01$
	H <sup>5</sup>	7.14	7.16	0.02					7.15	0.01
	$H^6$	10.50	10.69	0.19					10.62	0.12
	H <sup>1</sup>	8.75	8.95	0.20					9.75	1.00
	H <sup>2</sup>	7.69	7.73	0.04					7.83	0.14
L12	H <sup>3</sup>	6.34	6.33	$-0.01$					6.25	$-0.09$
	H <sup>4</sup>	1.26	1.26	0.00					1.20	$-0.06$
	H <sup>5</sup>	16.09	15.88	$-0.21$					15.67	$-0.42$



<span id="page-26-0"></span>**4.1. The relationship between chemical shifts in the <sup>1</sup>H NMR spectra and basicity of free ligands** 

**Figure S27.** The relationship between chemical shifts (δ, ppm) of the signal H<sup>1</sup> in the <sup>1</sup>H NMR spectra (CDCl<sub>3</sub>, 25<sup>o</sup>C) and the pK<sub>a</sub> values of free ligands for complexes of the general formula: [Pd**L**<sub>2</sub>Cl<sub>2</sub>] (black line, slope = -0.1158, R<sup>2</sup> = 0.9196); [Pd**L**<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (red line, slope = -0.1180, R<sup>2</sup> = 0.7991); [Pd**L**<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub> (blue line, slope =  $-0.1751$ ,  $R^2 = 0.9183$ ) and free ligands **L** (grey line, slope =  $-0.0848$ ,  $R^2 = 0.8412$ ). Ligands of known  $pK_a$  values in the literature are included in the graph.

<span id="page-26-1"></span>



**Figure S28.** The relationship between chemical shift changes ( $\Delta\delta$ , ppm) of the signal H<sup>1</sup> in the <sup>1</sup>H NMR spectra (CDCl<sub>3</sub>, 25°C), where Δδ (H<sup>1</sup>) = δ<sub>complex</sub> – δ<sub>ligand</sub> and the pK<sub>a</sub> values of free ligands for complexes of the general formula: [PdL<sub>2</sub>Cl<sub>2</sub>] (black line, slope = -0.0310, R<sup>2</sup> = 0.9320); [PdL<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] (red line, slope  $= -0.0250$ , R<sup>2</sup> = 0.8856) and  $[PdL<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  (blue line, slope =  $-0.0896$ , R<sup>2</sup> = 0.9430). Ligands of known  $pK<sub>a</sub>$  values in the literature are included in the graph.



# <span id="page-27-0"></span>**5. <sup>1</sup>H NMR titration of [Pd(L2)4](NO3)2 with Et3N . HCl**

**Figure S29.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) titration spectra of  $[Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  with Et<sub>3</sub>N · HCl.

<span id="page-27-1"></span>



**Figure S30.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) titration spectra of [Pd(L2)<sub>2</sub>Cl<sub>2</sub>] with L2.

## <span id="page-28-0"></span>**7. Acid – base titrations of the Pd(II) complexes based on the ligand L2**



## <span id="page-28-1"></span>**7.1. <sup>1</sup>H NMR titration of [Pd(L2)2Cl2] with Et3N**

Figure S31. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of [Pd(L2)<sub>2</sub>Cl<sub>2</sub>] upon addition of Et<sub>3</sub>N.

<span id="page-28-2"></span>**7.2. <sup>1</sup>H NMR titration of [Pd(L2)2Cl2] with MSA**



**Figure S32.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of  $[Pd(L2)_2C_2]$  upon addition of MSA.



<span id="page-29-0"></span>**7.3. <sup>1</sup>H NMR titration of [Pd(L2)2(NO3)2] with Et3N**

**Figure S33.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of  $[Pd(L2)_2(NO_3)_2]$  upon addition of Et<sub>3</sub>N.

<span id="page-29-1"></span>**7.4. <sup>1</sup>H NMR titration of [Pd(L2)2(NO3)2] with MSA**



**Figure S34.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of [Pd(L2)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] upon addition of MSA.

## <span id="page-30-0"></span>**7.5. <sup>1</sup>H NMR titration of [Pd(L2)4](NO3)2 with Et3N**



**Figure S35.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of  $[Pd(L2)_4](NO_3)_2$  upon addition of different equivalents of  $Et<sub>3</sub>N$ .

## <span id="page-30-1"></span>**7.6. <sup>1</sup>H NMR titration of [Pd(L2)4](NO3)2 with MSA**



**Figure S36.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) titration spectra of [Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub> upon addition of different equivalents of MSA.

## <span id="page-31-0"></span>**8. Stability investigation of Pd(II) complexes at high temperature in DMSO**



**Figure S37.** The <sup>1</sup>H NMR spectra (300 MHz, DMSO- $d_6$ ) showing the stability of of  $[Pd(L2)_2Cl_2]$  during heating in 120°C for 6 h.



**Figure S38.** The <sup>1</sup>H NMR spectra (300 MHz, DMSO- $d_6$ ) showing the stability of of  $[Pd(L2)_2(NO_3)_2]$  during heating in 120°C for 6 h.



**Figure S39.** The <sup>1</sup>H NMR spectra (300 MHz, DMSO- $d_6$ ) showing the stability of of  $[Pd(L2)_4](NO_3)_2$  during heating in 120°C for 6 h.

## <span id="page-32-0"></span>**9. X-ray crystal structure analysis**

## <span id="page-32-1"></span>**9.1. Additional details for crystal structure solution and refinement**

The crystal of  $[Pd(L3)_2C1_2]$  was recognized as a non-merohedral twin. Twin law [1 0 0 0.74 -1] 0 0.17 0 -1], which correspond to a 2-fold rotation axis around [100] direct lattice direction, was determined using ROTAX. The "Make HKLF5" function in WinGX was used to convert the reflection data to the HKLF5 format.<sup>6</sup> The refinement process took into account reflections belonging from the larger domain that are not overlapping with reflections from the smaller domain. The twin fraction was refined at 0.480(6). The chosen crystal of [Pd(L4)<sub>2</sub>Cl<sub>2</sub>] used for X-ray measurement was also identified as a non-merohedral twin. ROTAX suggested a possible twin matrix [1 0 0 0 -1 0 -1 0 -1], corresponding to 180° rotation about [-201] reciprocal lattice direction. The refinement process was carried out in the same way as in  $[Pd(L3)_2Cl_2]$ and the BASF parameter was refined at 0.0695(9).

In [Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub> the O2, O2A, O3, and O3A oxygen atoms in nitrate ion are disordered over 2 positions with fixed occupancies at 0.5. Atoms belonging to the –COOMe group near the N2 pyridyl ring in the  $[Pd(L4)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  crystal structure are disordered over two positions and refined at fixed occupancies of 0.5. In  $[Pd(L7)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$ , the N4-pyridyl ring is disordered over two positions with occupancies constrained at 0.5. Two chloroform molecules are disordered. In one solvent molecule (C14 and C14A) all atoms are disordered, and in the other molecule (with the C15 carbon atom) chlorine atoms show disorder. The occupancies of the disordered atoms were refined with occupancies constrained at 0.5. A solvent molecule in the asymmetric unit of  $[Pd(L6)<sub>4</sub>](NO<sub>3</sub>)$ <sub>2</sub> could not be modeled satisfactorily and it was therefore removed from the electron density map using the solvent mask within Olex2.7

# <span id="page-33-0"></span>**9.2. Description of the X-ray structure of Pd(II) complexes**



**Table S14.** Crystal data and structure refinement for the complexes based on **L2** and **L3**.

	[Pd(L4) <sub>2</sub> (NO3) <sub>2</sub> ]	[Pd(L4) <sub>2</sub> Cl <sub>2</sub> ]	$[Pd(L4)4] (NO3)2$	[Pd(L5) <sub>2</sub> (NO3) <sub>2</sub> ]
<b>CCDC</b> deposit no.	2175531	2175522	2175532	2175528
Empirical formula	$C_{28}H_{28}N_8O_{20}Pd_2$ CHCl <sub>3</sub>	$C_{14}H_{14}N_2O_4Cl_2Pd$	$C_{28}H_{28}N_6O_{14}Pd \cdot$ H <sub>2</sub> O	$C_{14}H_{14}N_{4}O_{8}Pd$
Formula weight	1128.75	451.57	796.98	472.69
Temperature/ Κ	100.02(10)	100.01(10)	293(2)	293(2)
Crystal system	triclinic	monoclinic	triclinic	monoclinic
Space group a/Å	$P-1$ 11.6543(4)	P2 <sub>1</sub> /c 3.8243(2)	$P-1$ 10.0018(1)	P2 <sub>1</sub> /c 11.1872(4)
b/Å	11.6963(4)	9.6992(4)	10.2197(2)	7.4905(2)
c/Å	17.0748(6)	21.1957(8)	18.8404(4)	10.8438(3)
$\alpha$ /°	91.138(3)	90	103.607(2)	90
$\beta$ /°	98.120(3)	94.855(4)	90.370(1)	93.037(3)
$V^{\circ}$	119.739(4)	90	116.196(2)	90
$V/\AA$ <sup>3</sup>	1989.72(14)	783.39(5)	1665.99(6)	907.42(5)
Z, Z'	2, 1	2, 0.5	2, 1	2, 0.5
$p_{calc}/gcm^{-3}$	1.884	1.914	1.589	1.730
$\mu$ /mm <sup>-1</sup>	1.197	12.895	0.637	8.726
F(000)	1124	448	812	472
Crystal size/mm <sup>3</sup>	$0.43 \times 0.43 \times$	$0.08 \times 0.04 \times$	$0.20 \times 0.10 \times$	$0.85 \times 0.31 \times$ 0.11
Radiation/Å	0.36 Mo Ka	0.03 $Cu$ Ka	0.01 Mo Ka	Cu Kα
	$(\lambda = 0.71073)$	$(\lambda = 1.54184)$	$(\lambda = 0.71073)$	$(\lambda = 1.54184)$
$2\theta$ range/ $\degree$				7.914 to
	5.772 to 58.354	8.374 to 150.814	4.558 to 55.468	152.288
Index ranges	$-15 \le h \le 14$	$-4 \leq h \leq 4$	$-12 \le h \le 12$	$-13 \le h \le 13$
	$-16 \le k \le 15$	$-12 \le k \le 12$	$-13 \le k \le 13$	$-8 \leq k \leq 9$
	$-21 \le   \le 22$	$-26 \leq l \leq 26$	$-24 \le   \le 24$	$-11 \le i \le 13$
<b>Reflections</b> collected	26178	4741	100939	3615
Independent reflections	9330 $[R_{int} = 0.0260,$ $R_{\text{sigma}} = 0.0342$	1532 $[R_{\text{sigma}} = 0.0260]$	7223 $[R_{\text{int}} = 0.0590,$ $R_{\text{sigma}} = 0.0355$ ]	1846 $[R_{int} = 0.0284,$ $R_{\text{sigma}} = 0.0275$
Reflections with $l \geq 2\sigma$ (I)	7930	1452	6111	1606
Data/restraint s/parameters	9330/0/566	1532/0/108	7223/0/486	1846/0/125
Final R	$R_1$ = 0.0277	$R_1 = 0.0367$	$R_1 = 0.0501$	$R_1 = 0.0563$
indexes $  \ge$ $2\sigma$ (l)]	$wR_2 = 0.0596$	$wR_2 = 0.1044$	$wR2 = 0.1181$	$wR_2 = 0.1835$
Final R	$R_1$ = 0.0371	$R_1 = 0.0382$	$R_1 = 0.0670$	$R_1 = 0.0596$
indexes (all	$wR_2 = 0.0632$	$wR_2 = 0.1057$	$wR_2 = 0.1241$	$wR_2 = 0.1918$
data)				
Goodness-of- fit on $F2$	1.024	1.140	1.204	1.162

**Table S15.** Crystal data and structure refinement for the complexes based on **L4** and **L5**.





**Table S16.** Crystal data and structure refinement for the complexes based on **L6**.

**Table S17.** Crystal data and structure refinement for the complexes based on **L7**.




<sup>a</sup> Two halves of complex molecules in the asymmetric unit.

# **9.3. ORTEP representations of Pd(II) complexes**



**Figure S40.** A view of the  $[Pd(L2)_2(NO_3)_2]$  asymmetric unit, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.



Figure S41. A view of the [Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub> structure, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level. H atoms are omitted for clarity. In nitrate counterion the O2, O2A, O3, and O3A oxygen atoms are disordered over 2 positions with fixed occupancies at 0.5. Symmetry code: *(a)* 1−x, 1−y, 1−z.



Figure S42. A view of the [Pd(L3)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>] asymmetric unit, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.



**Figure S43.** A view of the structure of [Pd(L3)<sub>2</sub>Cl<sub>2</sub>], showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. Symmetry code: *(a)* 1−x, −y, 1−z.



**Figure S44.** A view of the fragment of  $[Pd(L4)_2(NO_3)_2]$  crystal structure, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. H atoms are omitted for clarity. Symmetry codes: *(a)* 2−x, 1−y, 1−z; *(b)* − x, 1−y, −z.



**Figure S45.** A view of the  $[Pd(L4)_2Cl_2]$  complex molecule with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. Symmetry code: *(a)* −x, 1−y, −z.



**Figure S46.** A view of the  $[Pd(L4)_4](NO_3)_2$  asymmetric unit, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. H atoms are omitted for clarity. The -COOMe group near the N2-pyridyl ring are disordered over two positions and refined at fixed occupancies of 0.5.



**Figure S47.** A view of the structure of  $[Pd(L5)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>]$ , showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. Symmetry code: *(a)* 1−x, 2−y, 1−z.





**Figure S48.** A view of the  $[Pd(L6)_2Cl_2]$  structure, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. Symmetry code: *(a)* 2−x, 2−y, −z.



**Figure S49.** A view of the structure of  $[Pd(L6)_4](NO_3)_2$  with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. H atoms are omitted for clarity. Symmetry code: *(a)* 1−x, 1−y, 1−z. Solvent molecules were not modelled.



Figure S50. A view of the  $[Pd(L7)_2Cl_2]$  complex molecule, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. Symmetry code: *(a)* −x, 1−y, 1−z.



**Figure S51.** A view of the asymmetric unit of  $[Pd(L7)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>]$  with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.



**Figure S52.** The asymmetric unit of the  $[Pd(L7)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  2CHCl<sub>3</sub> with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. The disordered fragments are omitted for clarity.

# **9.4. Weak interactions in the crystal structures**



**Figure S53.** The weak interactions within the crystal structure of *trans*-[Pd(L2)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>].



**Figure S54.** The weak interactions within the crystal structure of *trans*-[Pd(L3)<sub>2</sub>Cl<sub>2</sub>].



**Figure S55.** The weak interactions within the crystal structure of *trans*-[Pd(L3)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>].



**Figure S56.** The weak interactions within the crystal structure of  $[Pd(L4)_2Cl_2]$ .



**Figure S57.** The weak interactions within the crystal structure of  $[Pd(L5)_2(NO_3)_2]$ .

# **10.Comparison of selected parameters for crystals of Pd(II) complexes**



**Table S18.** Selected geometric parameters for Pd(II) complexes based on the ligands **L1**-**L7**.







a Pd(II)–Cl or Pd(II)–O bond lengths in disubstituted complexes. Pd(II)…O non-bonded distance in tetra-substituted complexes. <sup>b</sup> Mean coordination plane PdN<sub>2</sub>Cl<sub>2</sub> or PdN<sub>2</sub>O<sub>2</sub> disubstituted complexes or PdN<sub>4</sub> in tetra-substituted complexes.  $c$  Structures that are packing polymorphs.



Table S19. C-H  $\cdot\cdot$ O interactions in the structure of disubstituted complexes with NO<sub>3</sub> counterions with the participation of protons closest to the pyridyl-*N* atoms of ligand molecules.

Table S20. C-H ··· CI interactions in disubstituted complexes with CI counterions with the participation of protons closest to the pyridyl-*N* atoms of ligand molecules.



**Table S21.** C-H $\cdots$ O interactions in tetra-substituted complexes with  $NO<sub>3</sub>$  counterions with the participation of protons closest to the pyridyl-*N* atoms of ligand molecules.





a The atoms with partial occupancy (50%).

## **11.Investigation of catalytic activity in the Suzuki-Miyaura cross-coupling**

#### **11.1. Reaction development for the Suzuki-Miyaura cross-coupling**

**Table S22.** Reaction development for the Suzuki-Miyaura cross-coupling between phenylboronic acid and 4'-bromoacetophenone.<sup>a</sup>



<sup>a</sup> Reaction conditions: 4'-bromoacetophenone (0.2 mmol, 1 equiv.), phenylboronic acid (0.24 mmol, 1.2 equiv.), base (0.4 mmol, 2 equiv.) and the complex  $[Pd(L2)_4](NO_3)_2$  were stirred in appropriate solvent  $(2 \text{ mL})$  at indicated temperature under air atmosphere.  $b$  Determined by GC measurement of 4'-bromoacetophenone decay.  $\circ$  As 2 M aqueous solution.

## **11.2. Catalytic activity of Pd(II) complexes based on pyridine ligands in the Suzuki-Miyaura reaction**



**Table S23.** Catalytic activity of Pd(II) complexes based on pyridine ligands in the Suzuki-Miyaura crosscoupling between 4'-bromoacetophenone and phenylboronic acid.<sup>a</sup>

<sup>a</sup> Reaction conditions: 4'-bromoacetophenone (0.2 mmol, 1 equiv.), phenylboronic acid (0.24 mmol, 1.2 equiv.), base (0.4 mmol, 2 equiv.) and Pd(II) complex (0.1 mol%) were stirred in toluene (2 mL) at 80 $\degree$ C under air atmosphere for 2 h.  $\frac{b}{c}$  Determined by GC measurement of 4'-bromoacetophenone decay as the average of three results.

## **11.3. General synthetic procedure for the Suzuki-Miyaura cross-coupling**

A reaction vessel equipped with a stirring bar was charged with aryl bromide **1a-c** (1.0 mmol, 1.0 equiv.) and arylboronic acid **2a-c** (1.2 mmol, 1.2 equiv.) which were dissolved in toluene (10 mL). After, the catalyst  $[Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  (0.001 mmol, 0.001 equiv.) as a solution in chloroform (0.05 mL) and solid  $K_3PO_4$  (2.0 mmol, 2.0 equiv.) were added. The vial was sealed and the reaction mixture was heated for 2 h at 80°C. The resulting solution was then cooled to room temperature, diluted with dichloromethane (50 mL) and washed with distilled water (40 mL). The collected aqueous phase was extracted with dichloromethane ( $2 \times 50$  mL). The organic layers were gathered, dried over  $Na<sub>2</sub>SO<sub>4</sub>$ , filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel to obtain the desired products **3aa-cc**.

## **11.4. Characterization of the cross-coupling products**

## **11.4.1. 4-acetylbiphenyl (3aa)<sup>12</sup>**



The reaction of 4'-bromoacetophenone **1a** (1 mmol, 199 mg) with phenylboronic acid **2a** (1.2 mmol, 146 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 20:1) gave 4 acetylbiphenyl **3aa** in the form of white solid. Yield: 93%, 182 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 8.04 (d, *J* = 8.4 Hz, 2H), 7.69 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 7.2 Hz, 2H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.41 (t, *J* = 7.4 Hz, 1H), 2.64 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 197.88, 145.92, 140.02, 135.99, 129.09, 129.05, 128.37, 127.41, 127.36, 26.82.

# **11.4.2. 1-(4'-trifluoromethyl-biphenyl-4-yl)-ethanone (3ab)<sup>13</sup>**



The reaction of 4'-bromoacetophenone **1a** (1 mmol, 199 mg) with 4- **CF<sup>3</sup>** (trifluoromethyl)phenylboronic acid **2b** (1.2 mmol, 228 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 10:1) gave 1-(4'-trifluoromethyl-biphenyl-4-yl)-ethanone **3ab** in the form of white solid. Yield: 84%, 222 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 8.06 (d, *J* = 8.4 Hz, 2H), 7.73 (s, 4H), 7.70 (d, *J* = 8.4 Hz, 2H), 2.65 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl3) δ = 197.70, 144.32, 143.55, 136.74, 130.39 (q, *J* = 32.5 Hz), 129.19, 127.76, 127.61, 126.96, 126.05 (q, *J* = 3.8 Hz), 124.26 (q, *J* = 272.0 Hz), 26.86.

## **11.4.3. 1-(4'-methyl-biphenyl-4-yl)-ethanone (3ac)<sup>14</sup>**



The reaction of 4'-bromoacetophenone **1a** (1 mmol, 199 mg) with 4 tolylboronic acid **2c** (1.2 mmol, 163 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 25:1) gave 1- (4'-methyl-biphenyl-4-yl)-ethanone **3ac** in the form of white solid. Yield: 90%, 189 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 8.02 (d, *J* = 8.4 Hz, 2H), 7.67 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 2.63 (s, 3H), 2.41 (s, 3H).

 $13C$  NMR (151 MHz, CDCl<sub>3</sub>) δ = 197.87, 145.85, 138.37, 137.09, 135.74, 129.82, 129.04, 127.23, 127.08, 26.79, 21.31.

## **11.4.4. Biphenyl (3ba)<sup>12</sup>**



The reaction of bromobenzene **1b** (1 mmol, 105 μL) with phenylboronic acid **2a** (1.2 mmol, 146 mg) according to the general procedure (flash chromatography: hexane) gave biphenyl **3ba** in the form of white solid. Yield: 77%, 119 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.60 (d, *J* = 7.2 Hz, 4H), 7.45 (t, *J* = 7.6 Hz, 4H), 7.35 (t, *J* = 7.4 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 141.38, 128.89, 127.39, 127.31.

## **11.4.5. 4-(trifluoromethyl)biphenyl (3bb)<sup>13</sup>**



The reaction of bromobenzene **1b** (1 mmol, 105 μL) with 4- **CF3**(trifluoromethyl)phenylboronic acid **2b** (1.2 mmol, 228 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 40:1) gave 4-(trifluoromethyl)biphenyl **3bb** in the form of white solid. Yield: 81%,

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.70 (s, 4H), 7.60 (d, J = 7.5 Hz, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.41 (t, *J* = 7.3 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl3) δ = 144.87, 139.92, 129.48 (q, *J* = 32.7 Hz), 129.13, 128.32, 127.57, 127.43, 125.85 (q, *J* = 3.8 Hz), 124.45 (q, *J* = 272.0 Hz).

# **11.4.6. 4-phenyltoluene (3bc)<sup>15</sup>**



The reaction of bromobenzene **1b** (1 mmol, 105 μL) with 4-tolylboronic acid **2c** (1.2 mmol, 163 mg) according to the general procedure (flash chromatography: hexane) gave 4-phenyltoluene **3bc** in the form of white solid. Yield: 70%, 118 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.59 (d, J = 7.3 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.43 (t, J = 7.7 Hz, 2H), 7.34 (t, *J* = 7.4 Hz, 1H), 7.26 (d, *J* = 7.7 Hz, 2H), 2.40 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 141.30, 138.50, 137.16, 129.61, 128.85, 127.14, 127.12, 127.10, 21.25.

## **11.4.7. 3,5-dimethoxybiphenyl (3ca)<sup>16</sup>**



The reaction of 1-bromo-3,5-dimethoxybenzene **1c** (1 mmol, 217 mg) with phenylboronic acid **2a** (1.2 mmol, 146 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 10:1 to 9:1) gave 3,5-dimethoxybiphenyl **3ca** in the form colorless yellow oil. Yield: 90%, 193 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.58 (d, *J* = 7.1 Hz, 2H), 7.43 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.4 Hz, 1H), 6.74 (d, *J* = 2.2 Hz, 2H), 6.48 (t, *J* = 2.2 Hz, 1H), 3.85 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 161.18, 143.64, 141.35, 128.84, 127.69, 127.34, 105.61, 99.43, 55.57.

## **11.4.8. 3,5-dimethoxy-4'-(trifluoromethyl)-biphenyl (3cb)<sup>17</sup>**



The reaction of 1-bromo-3,5-dimethoxybenzene **1c** (1 mmol, 217 mg) **CF<sup>3</sup>** with 4-(trifluoromethyl)phenylboronic acid **2b** (1.2 mmol, 228 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 25:1 to 20:1) gave 3,5-dimethoxy-4'- (trifluoromethyl)-biphenyl **3cb** in the form of white solid. Yield: 78%, 220 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.68 (s, 4H), 6.72 (d, J = 2.2 Hz, 2H), 6.51 (t, J = 2.2 Hz, 1H), 3.86 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl3) δ = 161.36, 144.85, 142.10, 129.74 (q, *J* = 32.5 Hz), 127.64, 125.79 (q, *J* = 3.7 Hz), 124.39 (q, *J* = 271.8 Hz), 105.78, 100.09, 55.63.

## **11.4.9. 3,5-dimethoxy-4'-methyl-biphenyl (3cc)<sup>16</sup>**



The reaction of 1-bromo-3,5-dimethoxybenzene **1c** (1 mmol, 217 mg) with 4-tolylboronic acid **2c** (1.2 mmol, 163 mg) according to the general procedure (flash chromatography: hexane/ethyl acetate 30:1) gave 3,5 dimethoxy-4'-methyl-biphenyl **3cc** in the form of colorless oil. Yield: 76%, 173 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.48 (d, *J* = 8.0 Hz, 2H), 7.24 (d, *J* = 7.9 Hz, 2H), 6.73 (d, *J* = 2.2 Hz, 2H), 6.46 (t, *J* = 2.2 Hz, 1H), 3.85 (s, 6H), 2.40 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 161.16, 143.56, 138.45, 137.51, 129.55, 127.16, 105.42, 99.17, 55.55, 21.26.



**11.5. NMR spectra of the cross-coupling products**

**Figure S58.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of 4-acetylbiphenyl **3aa**.



**Figure S59.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 4-acetylbiphenyl **3aa**.





**Figure S61.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 1-(4'-trifluoromethyl-biphenyl-4-yl)-ethanone **3ab**.



**Figure S62.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of 1-(4'-methyl-biphenyl-4-yl)-ethanone **3ac**.



**Figure S63.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 1-(4'-methyl-biphenyl-4-yl)-ethanone **3ac**.







Figure S66. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of 4-(trifluoromethyl)biphenyl 3bb.



Figure S67. <sup>13</sup>C NMR spectrum (151 MHz, CDCl<sub>3</sub>) of 4-(trifluoromethyl)biphenyl 3bb.





**Figure S69.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 4-phenyltoluene **3bc**.





**Figure S71.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 3,5-dimethoxybiphenyl **3ca**.



**Figure S73.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 3,5-dimethoxy-4'-(trifluoromethyl)-biphenyl **3cb**.



Figure S74. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of 3,5-dimethoxy-4'-methyl-biphenyl 3cc.



**Figure S75.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of 3,5-dimethoxy-4'-methyl-biphenyl **3cc**.

#### **12.Investigation of catalytic activity in the Suzuki-Miyaura cross-coupling**

#### **12.1. Reaction development for the Heck reaction**



Table S24. Reaction development for the Heck cross-coupling between styrene and iodobenzene.<sup>a</sup>

a Reaction conditions: iodobenzene (0.2 mmol, 1 equiv.), styrene (0.24 mmol, 1.2 equiv.), base and the complex  $[Pd(L2)<sub>4</sub>](NO<sub>3</sub>)<sub>2</sub>$  were stirred in appropriate solvent (2 mL) at indicated temperature under air atmosphere. **b** Determined by GC measurement of iodobenzene decay.

## **12.2. Catalytic activity of Pd(II) complexes based on pyridine ligands in the Heck reaction**

**Table S25.** Catalytic activity of Pd(II) complexes based on pyridine ligands in the Heck cross-coupling between styrene and iodobenzene.<sup>a</sup>



<sup>a</sup> Reaction conditions: iodobenzene (0.2 mmol, 1 equiv.), styrene (0.24 mmol, 1.2 equiv.), Et<sub>3</sub>N (1.0 mmol, 5 equiv.) and Pd(II) complex (0.1 mol%) were stirred in DMSO (2 mL) at 120 $\degree$ C under air atmosphere for 2 h.  $\rm{^b}$  Determined by GC measurement of iodobenzene decay as the average of three results. <sup>c</sup> Determined by GC analysis with the area normalization method.

## **12.3. General synthetic procedure for the Heck cross-coupling**

A reaction vessel equipped with a stirring bar was charged with aryl iodide **4a-c** (1.0 mmol, 1.0 equiv.) and olefin **5a-c** (1.2 mmol, 1.2 equiv.) which were dissolved in DMSO (10 mL). After, the catalyst  $[Pd(L2)<sub>a</sub>](NO<sub>3</sub>)$ <sub>2</sub> (0.001 mmol, 0.001 equiv.) as a solution in DMSO (0.05 mL) and  $Et<sub>3</sub>N$  (5.0 mmol, 5.0 equiv.) were added. The vial was sealed and the reaction mixture was heated for 6 h at 120°C. The resulting solution was then cooled to room temperature, diluted with ethyl acetate (50 mL) and washed with icy distilled water (40 mL). The collected aqueous phase was extracted with ethyl acetate (2  $\times$  50 mL). The organic layers were gathered, dried over  $Na<sub>2</sub>SO<sub>4</sub>$ , filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel to obtain the desired products **6aa-cc**.

## **12.4. Characterization of the cross-coupling products**

## **12.4.1. (***E***)-stilbene (6aa)<sup>18</sup>**



The reaction of iodobenzene **4a** (1 mmol, 112 μL) with styrene **5a** (1.2 mmol, 138 μL) according to the general procedure (flash chromatography: hexane) gave (*E*)-stilbene **6aa** in the form of white solid. Yield: 89%, 160 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.54 (d, *J* = 7.3 Hz, 4H), 7.38 (t, *J* = 7.7 Hz, 4H), 7.28 (t, *J* = 7.4 Hz, 2H), 7.13 (s, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 137.47, 128.83, 128.82, 127.76, 126.65.

## **12.4.2. Methyl (***E***)-cinnamate (6ab)<sup>18</sup>**



The reaction of iodobenzene **4a** (1 mmol, 112 μL) with methyl acrylate **5b O** (1.2 mmol, 109 μL) according to the general procedure (flash chromatography: hexane/ethyl acetate 10:1) gave methyl (*E*)-cinnamate **O 6ab** in the form of light yellow solid. Yield: 90%, 146 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.70 (d, *J* = 16.0 Hz, 1H), 7.53 – 7.52 (m, 2H), 7.39 – 7.38 (m, 2H), 6.45 (d, *J* = 16.0 Hz, 1H), 3.81 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 167.56, 145.00, 134.52, 130.43, 129.02, 128.20, 117.94, 51.84.

## **12.4.3. (***E***)-4-bromostilbene (6ba)<sup>19</sup>**



The reaction of 1-bromo-4-iodobenzene **4b** with styrene **5a** (1.2 mmol, 138 μL) according to the general procedure (flash chromatography: hexane) gave (*E*)-4-bromostilbene **6ba** in the form of white solid. Yield: 78%, 202 mg.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ = 7.51 (d, J = 7.2 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.39 – 7.37 (m, 4H), 7.29 (t, *J* = 6.7 Hz, 1H), 7.10 (d, *J* = 16.3 Hz, 1H), 7.04 (d, *J* = 16.3 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 137.19, 136.52, 132.02, 129.67, 128.99, 128.21, 128.15, 127.64, 126.80, 121.55.

## **12.4.4. Methyl (***E***)-4-bromocinnamate (6bb)<sup>20</sup>**



The reaction of 1-bromo-4-iodobenzene **4b** (1 mmol, 283 mg) with **O** methyl acrylate **5b** (1.2 mmol, 109 μL) according to the general procedure (flash chromatography: hexane/ethyl acetate 20:1) gave **O** methyl (*E*)-4-bromocinnamate **6bb** in the form of pale yellow solid.

Yield: 91%, 219 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.62 (d, *J* = 16.0 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.5 Hz, 2H), 6.42 (d, *J* = 16.0 Hz, 1H), 3.81 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 167.29, 143.62, 133.43, 132.29, 129.58, 124.69, 118.64, 51.95.

#### **12.4.5. (***E***)-4,4'-dibromostilbene (6bc)<sup>21</sup>**



The reaction of 1-bromo-4-iodobenzene **4b** (1 mmol, 283 mg) with **Br** 4-bromostyrene **5c** (1.2 mmol, 157 μL) according to the general procedure (flash chromatography: hexane) gave (*E*)-4,4' dibromostilbene **6bc** in the form of white solid. Yield: 74%, 250 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.48 (d, *J* = 8.5 Hz, 4H), 7.36 (d, *J* = 8.5 Hz, 4H), 7.02 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 136.05, 132.00, 128.27, 128.15, 121.79.

#### **12.4.6. (***E***)-4-acetylstilbene (6ca)<sup>22</sup>**



The reaction of 4-iodoacetophenone **4c** (1 mmol, 222 mg) with styrene **5a** (1.2 mmol, 138 μL) according to the general procedure (flash chromatography: hexane/ethyl acetate 15:1 to 10:1) gave (*E*)- 4-acetylstilbene **6ca** in the form of white solid. Yield: 55%, 122 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.96 (d, *J* = 8.4 Hz, 2H), 7.59 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 7.4 Hz, 2H), 7.39 (t, *J* = 7.7 Hz, 2H), 7.31 (t, *J* = 7.3 Hz, 1H), 7.23 (d, *J* = 16.3 Hz, 1H), 7.14 (d, *J* = 16.3 Hz, 1H), 2.61 (s, 3H). **O**

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 197.59, 142.14, 136.83, 136.09, 131.59, 129.01, 128.93, 128.45, 127.58, 126.95, 126.63, 26.74.

#### **12.4.7. Methyl (***E***)-4-acetylcinnamate (6cb)<sup>23</sup>**



The reaction of 4-iodoacetophenone **4c** (1 mmol, 222 mg) with methyl acrylate **5b** (1.2 mmol, 109 μL) according to the general procedure (flash chromatography: hexane/ethyl acetate 8:2) gave **O** methyl (*E*)-4-acetylcinnamate **6cb** in the form of pale yellow solid. Yield: 88%, 180 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.96 (d, *J* = 8.4 Hz, 2H), 7.70 (d, *J* = 16.0 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 6.52 (d, *J* = 16.0 Hz, 1H), 3.82 (s, 3H), 2.61 (s, 3H).

 $13C$  NMR (151 MHz, CDCl<sub>3</sub>) δ = 197.40, 167.04, 143.42, 138.82, 138.17, 128.98, 128.27, 120.46, 52.04, 26.82.

#### **12.4.8. (***E***)-4-acetyl-4'-bromostilbene (6cc)**



The reaction of 4-iodoacetophenone **4c** (1 mmol, 222 mg) with 4-bromostyrene **5c** (1.2 mmol, 157 μL) according to the general procedure (flash chromatography: hexane/ethyl acetate 9:1 to 8:2) gave (*E*)-4-acetyl-4'-bromostilbene **6cc** in the form of pale yellow solid. Yield: 80%, 241 mg.

<sup>1</sup>H NMR (600 MHz, CDCl3) δ = 7.95 (d, *J* = 8.4 Hz, 2H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.5 Hz, 2H), 7.40 (d, *J* = 8.5 Hz, 2H), 7.15 (d, *J* = 16.4 Hz, 1H), 7.11 (d, *J* = 16.3 Hz, 1H), 2.61 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ = 197.56, 141.72, 136.30, 135.78, 132.07, 130.26, 129.05, 128.38, 128.29, 126.70, 122.27, 26.75.





**Figure S76.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of (*E*)-stilbene **6aa**.



**Figure S77.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of (*E*)-stilbene **6aa**.



**Figure S78.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of methyl (*E*)-cinnamate **6ab**.



**Figure S79.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of methyl (*E*)-cinnamate **6ab**.



**Figure S80.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of (*E*)-4-bromostilbene **6ba**.



Figure S81. <sup>13</sup>C NMR spectrum (151 MHz, CDCl<sub>3</sub>) of methyl (*E*)-4-bromostilbene 6ba.



**Figure S82.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of methyl (*E*)-4-bromocinnamate **6bb**.



Figure S83. <sup>13</sup>C NMR spectrum (151 MHz, CDCl<sub>3</sub>) of methyl (*E*)-4-bromocinnamate 6bb.


**Figure S84.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of (*E*)-4,4'-dibromostilbene **6bc**.



**Figure S85.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of (*E*)-4,4'-dibromostilbene **6bc**.



**Figure S86.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of (*E*)-4-acetylstilbene **6ca**.



**Figure S87.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of (*E*)-4-acetylstilbene **6ca**.



**Figure S88.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of methyl (*E*)-4-acetylcinnamate **6cb**.



**Figure S89.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of methyl (*E*)-4-acetylcinnamate **6cb**.



**Figure S90.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl3) of (*E*)-4-acetyl-4'-bromostilbene **6cc**.



**Figure S91.** <sup>13</sup>C NMR spectrum (151 MHz, CDCl3) of (*E*)-4-acetyl-4'-bromostilbene **6cc**.

## **13.Influence of the type of pyridine ligands and the nature of Pd(II) complexes on GC yields in catalyzed reactions**



**13.1. The relationship between GC yield and the character of Pd(II) complex in the Suzuki-Miyaura cross-coupling**

**Figure S92.** The relationship between GC yield and the character of Pd(II) complex in the catalyzed Suzuki-Miyaura cross-coupling reaction. The data were collected for reactions performed for 2 h.

**13.2. The relationship between GC yield and the ligand basicity in the Suzuki-Miyaura cross-coupling**



**Figure S93.** The relationship between GC yield and the pKa values of the pyridine ligands in the catalyzed Suzuki-Miyaura cross-coupling reaction. The data were collected for reactions performed for 2 h. For ligands **L10-L12**, predicted pKa values provided by SciFinder.



**13.3. The relationship between GC yield and the character of Pd(II) complex in the Heck cross-coupling**

**Figure S94.** The relationship between GC yield and the character of Pd(II) complex in the catalyzed Heck cross-coupling reaction. The data were collected for reactions performed for 2 h.





Figure S95. The relationship between GC yield and the pKa values of the pyridine ligands in the catalyzed Heck cross-coupling reaction. The data were collected for reactions performed for 2 h. For ligands **L10-L12**, predicted pKa values provided by SciFinder.

## **14.References**

- 1. Martins, F. J.; Lima, R. M.; Santos, J. A. d.; Machado, P. d. A.; Coimbra, E. S.; Silva, A. D. d.; Raposo, N. R. B., Biological Properties of Heterocyclic Pyridinylimines and Pyridinylhydrazones. *Lett. Drug. Des. Discov.* **2016,** *13*, 107-114.
- 2. Sirois, J. J.; Davis, R.; DeBoef, B., Iron-Catalyzed Arylation of Heterocycles via Directed C–H Bond Activation. *Org. Lett.* **2014,** *16* (3), 868-871.
- 3. Beck, D. E.; Reddy, P. V. N.; Lv, W.; Abdelmalak, M.; Tender, G. S.; Lopez, S.; Agama, K.; Marchand, C.; Pommier, Y.; Cushman, M., Investigation of the Structure–Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. *J. Med. Chem.*  **2016,** *59* (8), 3840-3853.
- 4. Sato, T.; Yoshida, T.; Al Mamari, H. H.; Ilies, L.; Nakamura, E., Manganese-Catalyzed Directed Methylation of C(sp2)–H Bonds at 25 °C with High Catalytic Turnover. *Org. Lett.*  **2017,** *19* (19), 5458-5461.
- 5. Walczak, A.; Stefankiewicz, A. R., pH-Induced Linkage Isomerism of Pd(II) Complexes: A Pathway to Air- and Water-Stable Suzuki–Miyaura-Reaction Catalysts. *Inorg. Chem.*  **2018,** *57* (1), 471-477.
- 6. Farrugia, L., WinGX and ORTEP for Windows: an update. *J. Appl. Crystallogr.* **2012,** *45* (4), 849-854.
- 7. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H., OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **2009,** *42* (2), 339-341.
- 8. J. Bruns, M. S.; Wickleder, M. S., *Z. Anorg. Allg. Chem.* **2014,** *640*, 2344.
- 9. Fronczek, F. R., Experimental Crystal Structure Determination CCDC 1402174, 2015.
- 10. Krogul, A.; Cedrowski, J.; Wiktorska, K.; Ozimiński, W. P.; Skupińska, J.; Litwinienko, G., Crystal structure, electronic properties and cytotoxic activity of palladium chloride complexes with monosubstituted pyridines. *Dalton Trans.* **2012,** *41* (2), 658-666.
- 11. Zordan, F.; Brammer, L., M−X···X'−C Halogen-Bonded Network Formation in MX2(4 halopyridine)2 Complexes (M = Pd, Pt; X = Cl, I; X' = Cl, Br, I). *Cryst. Growth Des.* **2006,** *6* (6), 1374-1379.
- 12. Ghonchepour, E.; Islami, M. R.; Tikdari, A. M., Efficient heterogenization of palladium by citric acid on the magnetite nanoparticles surface (Nano-Fe3O4@CA-Pd), and its catalytic application in C-C coupling reactions. *J. Organomet. Chem.* **2019,** *883*, 1-10.
- 13. Shi, S.; Meng, G.; Szostak, M., Synthesis of Biaryls through Nickel‐Catalyzed Suzuki– Miyaura Coupling of Amides by Carbon–Nitrogen Bond Cleavage. *Angew. Chem. Int. Ed.*  **2016,** *128* (24), 7073-7077.
- 14. Takahashi, R.; Kubota, K.; Ito, H., Air- and moisture-stable Xantphos-ligated palladium dialkyl complex as a precatalyst for cross-coupling reactions. *Chem. Commun.* **2020,** *56* (3), 407-410.
- 15. Ge, J.; Jiang, J.; Yuan, C.; Zhang, C.; Liu, M., Palladium nanoparticles stabilized by phosphine ligand for aqueous phase room temperature Suzuki-Miyaura coupling. *Tetrahedron Lett.* **2017,** *58* (12), 1142-1145.
- 16. Gao, P.; Szostak, M., Highly Selective and Divergent Acyl and Aryl Cross-Couplings of Amides via Ir-Catalyzed C–H Borylation/N–C(O) Activation. *Org. Lett.* **2020,** *22* (15), 6010- 6015.
- 17. Kang, K.; Huang, L.; Weix, D. J., Sulfonate Versus Sulfonate: Nickel and Palladium Multimetallic Cross-Electrophile Coupling of Aryl Triflates with Aryl Tosylates. *J. Am. Chem. Soc.* **2020,** *142* (24), 10634-10640.
- 18. Ye, Z.; Chen, F.; Luo, F.; Wang, W.; Lin, B.; Jia, X.; Cheng, J., Palladium-Catalyzed Mizoroki-Heck-Type Reaction of Aryl Trimethoxysilanes. *Synlett* **2009,** *2009* (13), 2198- 2200.
- 19. Jia, X.; Frye, L. I.; Zhu, W.; Gu, S.; Gunnoe, T. B., Synthesis of Stilbenes by Rhodium-Catalyzed Aerobic Alkenylation of Arenes via C–H Activation. *J. Am. Chem. Soc.* **2020,** *142* (23), 10534-10543.
- 20. Pape, S.; Daukšaitė, L.; Lucks, S.; Gu, X.; Brunner, H., An in Situ Generated Palladium on Aluminum Oxide: Applications in Gram-Scale Matsuda–Heck Reactions. *Org. Lett.*  **2016,** *18* (24), 6376-6379.
- 21. Desai, S. P.; Ye, J.; Zheng, J.; Ferrandon, M. S.; Webber, T. E.; Platero-Prats, A. E.; Duan, J.; Garcia-Holley, P.; Camaioni, D. M.; Chapman, K. W.; Delferro, M.; Farha, O. K.; Fulton, J. L.; Gagliardi, L.; Lercher, J. A.; Penn, R. L.; Stein, A.; Lu, C. C., Well-Defined Rhodium– Gallium Catalytic Sites in a Metal–Organic Framework: Promoter-Controlled Selectivity in

Alkyne Semihydrogenation to E-Alkenes. *J. Am. Chem. Soc.* **2018,** *140* (45), 15309- 15318.

- 22. Zhong, J.-J.; Liu, Q.; Wu, C.-J.; Meng, Q.-Y.; Gao, X.-W.; Li, Z.-J.; Chen, B.; Tung, C.-H.; Wu, L.-Z., Combining visible light catalysis and transfer hydrogenation for in situ efficient and selective semihydrogenation of alkynes under ambient conditions. *Chem. Commun.*  **2016,** *52* (9), 1800-1803.
- 23. Mahmoudi, H.; Valentini, F.; Ferlin, F.; Bivona, L. A.; Anastasiou, I.; Fusaro, L.; Aprile, C.; Marrocchi, A.; Vaccaro, L., A tailored polymeric cationic tag–anionic Pd(ii) complex as a catalyst for the low-leaching Heck–Mizoroki coupling in flow and in biomass-derived GVL. *Green Chem.* **2019,** *21* (2), 355-360.